rituximab
Rituximab is a drug used to treat Lymphoma, Chronic Lymphocytic Leukemia, Leukemia, and other conditions. Rituximab is being actively studied in 373 studies and prior, has been studied in 616.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
M.D. Anderson Cancer Center | M D Anderson Cancer Center | Ajay Gopal |
Hoffmann-La Roche | Mayo Clinic | Julie M Vose, MD |
National Cancer Institute (NCI) | University of Texas MD Anderson Cancer Center | Steven P. Treon, MD, PhD |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Active, not recruiting
- Prolymphocytic Leukemia
- +2 more
- Ibrutinib
- +4 more
- Houston, TexasM D Anderson Cancer Center
2022-02-08
Feb 8, 2022N
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +3 more
- Alisertib
- +3 more
- Bronx, New York
- +3 more
2022-04-05
Apr 5, 2022N
Active, not recruiting
- Ann Arbor Stage III Small Lymphocytic Lymphoma
- +7 more
- Ibrutinib
- +3 more
- Washington, District of Columbia
- +1 more
2022-04-05
Apr 5, 2022M
Recruiting
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- +6 more
- Acalabrutinib
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-02-08
Feb 8, 2022M
Active, not recruiting
- CCND1 Positive
- +6 more
- Ibrutinib
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-01-11
Jan 11, 2022F
Recruiting
- Burkitt Lymphoma
- +2 more
- Rituximab and Hyaluronidase Human
- +8 more
- Kampala, UgandaUCI-Fred Hutch Cancer Centre
2022-03-09
Mar 9, 2022N
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +5 more
- Atezolizumab
- +4 more
- Duarte, California
- +3 more
2022-04-05
Apr 5, 2022U
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +8 more
- Ixazomib Citrate
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2021-10-20
Oct 20, 2021M
Active, not recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +9 more
- Ibrutinib
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-02-03
Feb 3, 2022A
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
- Scottsdale, Arizona
- +9 more
2022-04-07
Apr 7, 2022O
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Dasatinib
- +4 more
- Portland, OregonOHSU Knight Cancer Institute
2021-12-27
Dec 27, 2021M
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Chimeric Antigen Receptor T-Cell Therapy
- +3 more
- Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
2022-03-08
Mar 8, 2022U
Terminated
- Lymphoid Leukemia
- +3 more
- Copanlisib
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2021-07-20
Jul 20, 2021N
Active, not recruiting
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Ibrutinib
- +4 more
- Washington, District of Columbia
- +6 more
2022-04-05
Apr 5, 2022M
Completed
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- +9 more
- Lenalidomide
- Rituximab
- Houston, TexasM D Anderson Cancer Center
2021-09-28
Sep 28, 2021M
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
- Houston, TexasM D Anderson Cancer Center
2021-11-22
Nov 22, 2021N
Active, not recruiting
- Steroid-Dependent Nephrotic Syndrome
- Rituximab
- Mycophenolate Mofetil
- Kolkata, West Bengal, IndiaNilratan Sircar Medical College and Hospital
2022-04-06
Apr 6, 2022W
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +7 more
- Saint Louis, MissouriWashington University School of Medicine
2022-02-02
Feb 2, 2022M
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- Rituximab
- Houston, TexasM D Anderson Cancer Center
2021-02-24
Feb 24, 2021L
Recruiting
- ANCA Associated Vasculitis
- Rituximab
- +3 more
- Leiden, Zuid-Holland, Netherlands
- +1 more
2021-09-06
Sep 6, 2021M
Recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- +7 more
- Houston, TexasM D Anderson Cancer Center
2022-03-03
Mar 3, 2022O
Active, not recruiting
- Central Nervous System Lymphoma
- Carboplatin
- +5 more
- Cincinnati, Ohio
- +3 more
2021-09-15
Sep 15, 2021U
Active, not recruiting
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
- Madison, WisconsinUniversity of Wisconsin
2021-10-07
Oct 7, 2021Y
Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Recruiting
- Diffuse Large B-Cell Lymphoma
- +2 more
- Cyclophosphamide
- +5 more
- Columbus, OhioOhio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022N
Completed
- Pulmonary Alveolar Proteinosis (PAP)
- Severe Mucocutaneous Candidiasis
- Rituximab
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022